TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12351376

Group type: EXPERIMENTAL
Intervention: Daunorubicin (group 1)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Idarubicin 10 mg/m(2) (group 2A)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Idarubicin 12 mg/m(2) (group 2B)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (BMT)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Idarubicin (compared to daunorubicin)
Number of subjects: 262
Study: 10445679

Group type: EXPERIMENTAL
Intervention: Clevidipine at 0.18 microg/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clevidipine at 0.91 microg/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clevidipine at 2.74 microg/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clevidipine at 5.48 microg/kg/min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8847094

Group type: EXPERIMENTAL
Intervention: Ragweed allergen (RWA) treatment of sera
Number of subjects: 80
Study: 2187700

Group type: EXPERIMENTAL
Intervention: Almitrine 50 mg b.d. p.o.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7322785

Group type: EXPERIMENTAL
Intervention: Audio feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Audiovisual feedback
Number of subjects: 48

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 48
Study: 30711416

Group type: EXPERIMENTAL
Intervention: CCZ (75 mg twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CCZ+RBV (1000/1200 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CCZ+RBV
Number of subjects: 24
Study: 28059912

Group type: EXPERIMENTAL
Intervention: Phenol injection
Number of subjects: 140

Group type: COMPARATOR
Intervention: Excision with open healing
Number of subjects: 140
Study: 26502966

Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxy progesterone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 60
Study: 23506464

Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Protective Behavioral Strategies Feedback (PBSF)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Alcohol Education (AE)
Number of subjects: 365
Study: 21298522

Group type: EXPERIMENTAL
Intervention: Single-port transumbilical total laparoscopic hysterectomy (SPLS-TLH)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Four-port total laparoscopic hysterectomy (TLH)
Number of subjects: 68
Study: 19141125

Group type: EXPERIMENTAL
Intervention: Basiliximab (Simulect) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (recipients without basiliximab injection)
Number of subjects: 0
Study: 18184535

Group type: EXPERIMENTAL
Intervention: d‐MPH bimodal release formulation (20 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: d‐MPH immediate release formulation (two 10 mg doses given 4 h apart)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: d,l‐MPH bimodal release formulation (40 mg)
Number of subjects: 25
Study: 15017215

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11573581

Group type: EXPERIMENTAL
Intervention: remifentanil/propofol (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: sufentanil/propofol (n=10)
Number of subjects: 20
Study: 9610998

Group type: EXPERIMENTAL
Intervention: Ring block
Number of subjects: 40

Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 40
Study: 7993707

Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies (aPL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic modalities
Number of subjects: 0
Study: 3251497

Group type: EXPERIMENTAL
Intervention: 75 mg of sustained release PPA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30698069

Group type: EXPERIMENTAL
Intervention: Initial treatment (radiotherapy for endometrial cancer)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Initial treatment (chemotherapy for ovarian cancer)
Number of subjects: 395

Group type: COMPARATOR
Intervention: No chemotherapy or early-stage disease
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Clinical characteristics (comorbidities, treatment, tumor stage)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Sociodemographic characteristics (socioeconomic status)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Cognitive and social functioning
Number of subjects: 395
Study: 28661205

Group type: EXPERIMENTAL
Intervention: Hemorrhagic shock induced using Wigger’s shock model, followed by blood reinfusion.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control animals (not specified how they were treated).
Number of subjects: 0
Study: 26429700

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with dihydroartemisinin‐piperaquine
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment with dihydroartemisinin‐piperaquine
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine
Number of subjects: 1546
Study: 23168523

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS)
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg BID)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study: 21148051

Group type: EXPERIMENTAL
Intervention: Insulin + AICAR (67 mg·kg(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin + placebo (saline)
Number of subjects: 10
Study: 18251611

Group type: EXPERIMENTAL
Intervention: Brushing + flossing + Listerine (N = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Brushing + flossing (N = 25)
Number of subjects: 50
Study: 16904415

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (20 microg of ethinylestradiol (EE)/100 microg of levonorgestrel)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (15 microg of EE/60 microg of gestodene)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Vaginal ring (15 microg of EE/120 microg of etonogestrel)
Number of subjects: 280

Group type: COMPARATOR
Intervention: All groups (combined oral contraceptives and vaginal ring)
Number of subjects: 280
Study: 12829654

Group type: EXPERIMENTAL
Intervention: Exercise training (heart rate‐controlled endurance training twice a week and supervised muscle strength training twice a week for 12 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment only (Control group)
Number of subjects: 50
Study: 10661003

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imaginal exposure
Number of subjects: 0
Study: 8965102

Group type: EXPERIMENTAL
Intervention: Specific training for neglect
Number of subjects: 3

Group type: COMPARATOR
Intervention: General cognitive intervention
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Neglect training (after switching from general cognitive intervention)
Number of subjects: 3
Study: 1701817

Group type: EXPERIMENTAL
Intervention: Gonococcal pilus vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Preexisting antibodies
Number of subjects: 20
Study: 6514179

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (8 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31145207

Group type: EXPERIMENTAL
Intervention: Topical insulin (TI) 1 unit/drop 4 times per day for 4 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard artificial tears (SAT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Topical insulin (TI)
Number of subjects: 160
Study: 30522397

Group type: EXPERIMENTAL
Intervention: Homemade street foods (e.g., fried cakes, stewed meat/fish/liver dishes)
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Hamburgers
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Stewed liver dishes
Number of subjects: 968
Study: 27742752

Group type: EXPERIMENTAL
Intervention: Self-controlled vocal exercise
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 199
Study: 26436491

Group type: EXPERIMENTAL
Intervention: TORS alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TORS plus adjuvant therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: TORS group
Number of subjects: 80
Study: 25152982

Group type: EXPERIMENTAL
Intervention: 36 weeks PEG‐RBV therapy (group B)
Number of subjects: 166

Group type: COMPARATOR
Intervention: 48 weeks PEG‐RBV therapy (group A)
Number of subjects: 166
Study: 21112054

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 μg 3 hours before MVA
Number of subjects: 600

Group type: COMPARATOR
Intervention: Vaginal placebo 3 hours before MVA
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 μg 3 hours before EVA
Number of subjects: 600

Group type: COMPARATOR
Intervention: Vaginal placebo 3 hours before EVA
Number of subjects: 600
Study: 19158210

Group type: EXPERIMENTAL
Intervention: Iron supplementation of 125 mg FeSO4 daily from 10 weeks to 9 months postpartum (IDA-Fe)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Placebo (IDA-PL)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (iron-sufficient mothers)
Number of subjects: 95
Study: 17479608

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 55 microg
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 110 microg
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 220 microg
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 440 microg
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 110 microg and 440 microg
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study: 15184207

Group type: EXPERIMENTAL
Intervention: FP Accuhaler 2000 microg/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FP Accuhaler 1000 microg/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MF Twisthaler 1600 microg/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MF Twisthaler 800 microg/day
Number of subjects: 21
Study: 19397013

Group type: EXPERIMENTAL
Intervention: Nurse-guided education program, facilitated telephone communication, and regularly scheduled follow-up visits with an internist (Intervention group, n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (Control group, n = 100)
Number of subjects: 200
Study: 9512223

Group type: EXPERIMENTAL
Intervention: Total cortisol concentration in follicular fluid from fertilized oocytes in 'low responder' patients (group 1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Total cortisol concentration in follicular fluid from fertilized oocytes in 'good responder' patients (group 2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Total cortisol concentrations in follicular fluid of unfertilized oocytes or empty follicles
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Total cortisol concentrations in follicular fluid
Number of subjects: 35
Study: 8040955

Group type: EXPERIMENTAL
Intervention: Immediate surgery
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Selective surgery (follow-up with ultrasonography or CT every 6 months)
Number of subjects: 1350
Study: 2725369

Group type: EXPERIMENTAL
Intervention: Training for lay subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training for medical students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training for teaching staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training for teaching staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training for medical students
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training for lay subjects
Number of subjects: 0
Study: 1130879

Group type: EXPERIMENTAL
Intervention: Intraluminal 5 FU (30mg/kg) with intravenous 5 FU (10mg/kg) on the first two postoperative days and 5 subsequent postoperative courses of oral 5 FU (90 mg/kg in each 18 day course) over one year period.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Intraluminal control (Saline) group.
Number of subjects: 156
Study: 30925507

Group type: EXPERIMENTAL
Intervention: Early parent interaction program
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 151
Study: 29065960

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both CPAP and MAD
Number of subjects: 42
Study: 26501118

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment (lansoprazole, clarithromycin, metronidazole)
Number of subjects: 3038

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3038
Study: 23596810

Group type: EXPERIMENTAL
Intervention: Korean red ginseng extract (1500 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21146763

Group type: EXPERIMENTAL
Intervention: Enhanced focus on physical appearance (Appearance)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Combined focus on appearance and health (Combined)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard behavioral intervention
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Satisfaction measures (Multidimensional Body‐Self Relations Questionnaire, Medical Outcomes Study Short Form‐36)
Number of subjects: 203
Study: 18585631

Group type: EXPERIMENTAL
Intervention: Ofloxacin administration after each BCG instillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16864926

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (CAA) - verapamil
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Beta-blocker (BB) - bisoprolol, atenolol or metoprolol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Digitalis (control)
Number of subjects: 29
Study: 12888781

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyproheptadine (4 mg)
Number of subjects: 0
Study: 11156042

Group type: EXPERIMENTAL
Intervention: PLA barrier in combination with DFDBA
Number of subjects: 30

Group type: COMPARATOR
Intervention: PLA barrier alone
Number of subjects: 30
Study: 9196381

Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg administered i.v. over 5 minutes)
Number of subjects: 10
Study: 10183117

Group type: EXPERIMENTAL
Intervention: Provider expertise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct experience
Number of subjects: 0
Study: 3085612

Group type: EXPERIMENTAL
Intervention: Thallium-201 myocardial scintigraphy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Other non-invasive investigations
Number of subjects: 32
Study: 31093939

Group type: EXPERIMENTAL
Intervention: Pharmacy interns
Number of subjects: 218

Group type: COMPARATOR
Intervention: Pharmacists
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Responses to ethical vignette scenarios
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Exposure to potential privacy breaches
Number of subjects: 218
Study: 29605319

Group type: EXPERIMENTAL
Intervention: 5-hydroxy-l-tryptophan (5-HTP) 1 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 5-hydroxy-l-tryptophan (5-HTP) with negative DCAD diet
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Negative DCAD diet
Number of subjects: 31

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 31
Study: 26944262

Group type: EXPERIMENTAL
Intervention: Single fraction of 28Gy
Number of subjects: 84

Group type: COMPARATOR
Intervention: 48Gy in four fractions of SABR
Number of subjects: 84
Study: 24579923

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 102

Group type: COMPARATOR
Intervention: IUI
Number of subjects: 102
Study: 23098865

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg daily for 10 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 19443519

Group type: EXPERIMENTAL
Intervention: Ismigen (one capsule daily for the first 10 days of three consecutive months)
Number of subjects: 63
Study: 17264722

Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sugammadex 8.0 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15479362

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11966949

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg acutely, 12.5 mg daily for 7 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propranolol (80 mg acutely, 80 mg daily for 7 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 36
Study: 9846467

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin eardrops plus aspiration in the clinic, n = 40 (47 ears)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Self-administered ciprofloxacin eardrops at home, n = 40 (48 ears)
Number of subjects: 80
Study: 8134058

Group type: EXPERIMENTAL
Intervention: Experimental clinic high-risk patients
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control clinic high-risk patients
Number of subjects: 290
Study: 2598571

Group type: COMPARATOR
Intervention: Ciprofloxacin administered alone (750 mg) as control treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 5 to 10 minutes after antacid (30 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 2 hours after antacid (30 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 4 hours after antacid (30 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 6 hours after antacid (30 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 2 hours after ranitidine (200 mg)
Number of subjects: 0
Study: 241181

Group type: EXPERIMENTAL
Intervention: Intermittent dosage schedules of antipsychotic preparations with reduced antiparkinsonic agents
Number of subjects: 300

Group type: COMPARATOR
Intervention: High doses of chlorpromazine
Number of subjects: 300
Study: 31386199

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 623
Study: 28804124

Group type: EXPERIMENTAL
Intervention: Imatinib (IM) at 400 mg/day
Number of subjects: 1551

Group type: EXPERIMENTAL
Intervention: Non-CML determinants
Number of subjects: 1551
Study: 26441006

Group type: EXPERIMENTAL
Intervention: risperidone or flupenthixol long acting injection
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 22
Study: 23616521

Group type: COMPARATOR
Intervention: Congruent (C)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Incongruent at preresponse level (PRIC)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Incongruent at response level (RIC)
Number of subjects: 3
Study: 21267072

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (target dose 7.2:2.4 mg/kg to 13.8:4.6 mg/kg) once daily for three days
Number of subjects: 456

Group type: COMPARATOR
Intervention: Chloroquine (standard dose) once daily for three days
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 456

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 456
Study: 19367302

Group type: EXPERIMENTAL
Intervention: Enforcement of age-restricted tobacco sales in the Central Coast intervention area
Number of subjects: 0
Study: 16223754

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (100 microl per dose)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 15349002

Group type: EXPERIMENTAL
Intervention: 12 mg buprenorphine sublingual
Number of subjects: 6

Group type: COMPARATOR
Intervention: i.v./sublingual placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: escalating i.v. buprenorphine (2, 4, 8, 12, and 16 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: i.v. administration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: sublingual administration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 12 mg i.v. dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 6
Study: 11739135

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg twice a day
Number of subjects: 82

Group type: COMPARATOR
Intervention: Combination of detection and treatment
Number of subjects: 82
Study: 9159681

Group type: EXPERIMENTAL
Intervention: Modified BENT incision (oblique incision centered on the steeper meridian)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Superior incision
Number of subjects: 68

Group type: COMPARATOR
Intervention: Temporal incision
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Modified BENT incision
Number of subjects: 68
Study: 8115730

Group type: EXPERIMENTAL
Intervention: 12% perfluoropropane gas
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20% perfluoropropane gas
Number of subjects: 30
Study: 3617996

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with MTX and 5-FU (therapy arm A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Systemic chemotherapy (therapy arm B)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy
Number of subjects: 85
Study: 28548904

Group type: EXPERIMENTAL
Intervention: Asthma Passport
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Asthma Passport (per-protocol analysis)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 222